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1. INTRODUCTION {#cam42758-sec-0005}
===============

Guidelines of the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO) recommend preoperative workup and postoperative measurements of serum carcinoembryonic antigen (CEA) every 3‐6 months for patients with rectal cancer who undergo curative resection.[1](#cam42758-bib-0001){ref-type="ref"}, [2](#cam42758-bib-0002){ref-type="ref"}, [3](#cam42758-bib-0003){ref-type="ref"} Both preoperative and early postoperative CEA levels are known to be prognostic factors after curative resection for rectal cancer, with elevated preoperative CEA[3](#cam42758-bib-0003){ref-type="ref"}, [4](#cam42758-bib-0004){ref-type="ref"}, [5](#cam42758-bib-0005){ref-type="ref"} as well as continuously elevated postoperative CEA being associated with worse survival.[6](#cam42758-bib-0006){ref-type="ref"}, [7](#cam42758-bib-0007){ref-type="ref"}, [8](#cam42758-bib-0008){ref-type="ref"}

In a recent study, recurrence‐free survival (RFS) of patients with postoperatively normalized CEA was shown to be similar to that of patients with normal preoperative CEA,[9](#cam42758-bib-0009){ref-type="ref"} suggesting that perioperative change in CEA, rather than preoperative level of CEA, is important in predicting prognosis in colon cancer. Meanwhile, rectal cancer differs from colon cancer in terms of survival and recurrence patterns,[10](#cam42758-bib-0010){ref-type="ref"} and thus, changes in CEA levels after curative resection might also differ.[8](#cam42758-bib-0008){ref-type="ref"} In this regard, the prognostic significance of preoperatively elevated but postoperatively normalized CEA in rectal cancer warrants further investigation.

Preoperative treatment such as chemoradiotherapy and chemotherapy prior to total mesorectal excision is the current standard for locally advanced rectal cancer in many Western countries.[11](#cam42758-bib-0011){ref-type="ref"} Meanwhile, in Japan, upfront surgery (total mesorectal excision plus lateral lymph node (LN) dissection) without any preoperative therapy is performed as the standard treatment for rectal cancer.[12](#cam42758-bib-0012){ref-type="ref"} This unique strategy in Japan allows for serial evaluation of perioperative CEA levels in patients with rectal cancer, without any influence of preoperative therapy.

This study aimed to investigate the prognostic impact of preoperative and early postoperative serum CEA in patients with stage I‐III rectal cancer who underwent curative resection, focusing mainly on the prognostic significance of preoperatively elevated and postoperatively normalized CEA following curative resection.

2. MATERIALS AND METHODS {#cam42758-sec-0006}
========================

2.1. Study population and design {#cam42758-sec-0007}
--------------------------------

The study population comprised patients with stage I‐III rectal adenocarcinoma who underwent curative resection at National Cancer Center Hospital in Japan from January 2000 to December 2015. According to the Japanese classification of colorectal, appendiceal, and anal carcinoma, the rectum is defined as the segment from the height of the inferior border of the second sacral vertebra to the superior border of the puborectal sling.[13](#cam42758-bib-0013){ref-type="ref"} Patients who underwent preoperative treatment such as chemoradiotherapy or chemotherapy were excluded, given the possible influence on preoperative serum CEA. Patients with elevated preoperative CEA, for whom early postoperative CEA measurements were not available, were also excluded from the analysis.

Preoperative CEA was defined as CEA measured immediately prior to surgery, and early postoperative CEA was defined as CEA measured within 3 months after surgery and before adjuvant chemotherapy. The reference range of CEA was set at ≤5 ng/ml. Patients were divided into the following three groups according to levels of preoperative and early postoperative CEA: normal preoperative CEA (normal group), elevated preoperative and normalized postoperative CEA (normalized group), and elevated preoperative and postoperative CEA (elevated group). RFS and overall survival (OS) were investigated in each group.

The Institutional Review Board (IRB) of the National Cancer Center Hospital approved this retrospective study (IRB code: 2017‐437).

2.2. Follow‐up {#cam42758-sec-0008}
--------------

Postoperative follow‐up consisted of serum CEA and CA19‐9 measurements every 3 months for the first 2 years, then every 6 months for 3 years; computed tomography (CT) every 6 months for 5 years; and colonoscopy in the first and third year, as described previously.[14](#cam42758-bib-0014){ref-type="ref"} Follow‐up data were documented prospectively until an event occurred, or until the study cutoff date of August 2018.

2.3. Statistical analysis {#cam42758-sec-0009}
-------------------------

Pearson\'s Chi‐square test and the Kruskal‐Wallis test were performed for categorical variables and continuous variables, respectively, to examine various factors in each group. Continuous variables are presented as median (interquartile range). RFS was defined as the interval between the date of surgery of primary cancer and the date of recurrence or death from all causes. OS was defined as the interval between the date of surgery of primary cancer and the date of death from all causes. Patients alive at the end of the follow‐up period were censored. The Kaplan‐Meier method was used to estimate RFS and OS. Differences in survival were assessed with the log‐rank test. Multivariable Cox proportional hazards regression models were subsequently fitted to evaluate factors independently associated with recurrence and death. Selection of covariates to be included in the multivariable analysis was performed based on information from previous studies.[5](#cam42758-bib-0005){ref-type="ref"}, [15](#cam42758-bib-0015){ref-type="ref"} The hazard function (smoothed hazard estimate) of recurrence or death, which conveys the instantaneous conditional recurrence or death rate at time *t*, was also analyzed [16](#cam42758-bib-0016){ref-type="ref"}, [17](#cam42758-bib-0017){ref-type="ref"} and expressed as the number of events per unit of time (months). Propensity score matching analysis was conducted in order to balance the distribution of covariates between the normal preoperative CEA group and elevated preoperative CEA group (which included the normalized and elevated subgroups), as described previously.[18](#cam42758-bib-0018){ref-type="ref"}, [19](#cam42758-bib-0019){ref-type="ref"} Multivariable logistic regression was used to generate propensity score‐predicting preoperative CEA status based on confounding covariates, including sex (male vs female), procedure (sphincter‐preserving vs non‐preserving), lymphatic invasion (present vs absent), venous invasion (present vs absent), and TNM stage (I/II vs III). Propensity scores were used for matching, which pair patients with normal preoperative CEA and patients with elevated preoperative CEA according to similarities in their baseline characteristics. Each patient with normal preoperative CEA was matched 1:1 with a patient with elevated preoperative CEA using the closest estimated propensity on the logit scale within a specified range (smaller than 0.05 of estimated logits as the caliper width) in order to reduce differences between the two groups, and outcomes in matched patients were compared and analyzed.

*P *\< .05 was considered statistically significant, and 95% confidence intervals (CIs) were calculated. Bonferroni correction for multiple comparisons was performed to compare outcomes. All statistical analyses were performed using the JMP14 software program (SAS Institute Japan Ltd., Tokyo, Japan) or R version 3.5.3 (R Project).

3. RESULTS {#cam42758-sec-0010}
==========

3.1. Study cohort characteristics {#cam42758-sec-0011}
---------------------------------

Figure [1](#cam42758-fig-0001){ref-type="fig"} shows the flowchart of patient selection and classification into three groups according to levels of preoperative and postoperative CEA. A total of 1661 stage I‐III rectal cancer patients who underwent curative resection were identified. Of these, 1490 patients were subjected to analysis, excluding 45 who underwent preoperative chemoradiotherapy or chemotherapy, and 126 with elevated preoperative CEA, for whom early postoperative CEA measurements were not available. Data on preoperative CEA were obtained from all patients; 1208 had normal preoperative CEA, 235 had elevated preoperative CEA which subsequently normalized postoperatively, and 47 had elevated preoperative CEA which persisted postoperatively.

![CONSORT diagram for patient selection. After exclusion of patients who underwent preoperative treatment (n = 45) and those with elevated preoperative CEA, those for whom postoperative CEA measurements were not available (n = 126), from the initially recruited patients with stage I‐III rectal cancer (n = 1661), the final number of analyzed patients was 1490](CAM4-9-653-g001){#cam42758-fig-0001}

Table [1](#cam42758-tbl-0001){ref-type="table"} summarizes patient clinicopathologic features by group. Patients with elevated postoperative CEA (elevated group) were older (*P* = .0016) and had poor tumor differentiation (*P* = .002), and those with elevated preoperative CEA (both the normalized and elevated groups) had more venous invasion (*P* \< .0001) and advanced tumor stage (*P* \< .0001). The tumor distance from the anal verge was longer in the normal group (*P* = .0197), and sphincter‐preserving surgery was performed more frequently in the normalized group (*P* \< .0001).

###### 

Patient characteristics

                                           All              Normal CEA (N = 1208)   Normalized CEA (N = 235)   Elevated CEA (N = 47)   *P* value
  ---------------------------------------- ---------------- ----------------------- -------------------------- ----------------------- -----------
  Age (years; median, IQR)                 62 (54, 69)      62 (54, 68)             61 (52, 68)                68 (59, 73)             .0016
  Operation year                                                                                                                       .992
  2000‐2007                                816 (55)         662 (55)                128 (54)                   26 (55)                  
  2008‐2015                                674 (45)         546 (45)                107 (46)                   21 (45)                  
  Sex                                                                                                                                  .647
  Male                                     1001 (67)        806 (67)                161 (69)                   34 (72)                  
  Female                                   489 (33)         402 (33)                74 (31)                    13 (28)                  
  Tumor distance from the anal verge, cm                                                                                               .0197
  ≤5                                       670 (45)         523 (43)                125 (53)                   22 (53)                  
  \>5                                      820 (55)         685 (57)                110 (47)                   25 (47)                  
  Clinical stage                                                                                                                       \<.0001
  I                                        544 (37)         518 (43)                18 (8)                     8 (17)                   
  II                                       392 (26)         302 (25)                71 (30)                    19 (40)                  
  III                                      554 (37)         388 (32)                146 (62)                   20 (43)                  
  Operative procedure                                                                                                                  \<.0001
  Sphincter‐preserving                     1246 (84)        1040 (86)               168 (71)                   38 (81)                  
  Non‐preserving                           244 (16)         168 (14)                67 (29)                    9 (19)                   
  Tumor differentiation                                                                                                                .0015
  Well                                     803 (54)         681 (56)                98 (42)                    24 (51)                  
  Moderate                                 615 (41)         472 (39)                125 (53)                   18 (38)                  
  Poor                                     71 (4)           54 (4)                  12 (5)                     5 (11)                   
  Not available                            1 (0.07)         1 (0.08)                0                          0                        
  Lymphatic invasion                                                                                                                   .1204
  Yes                                      457 (30)         352 (29)                87 (37)                    18 (38)                  
  No                                       1028 (69)        852 (70)                147 (62)                   29 (62)                  
  Not available                            5 (0.34)         4 (0.33)                1 (0.43)                   0                        
  Venous invasion                                                                                                                      \<.0001
  Yes                                      828 (55)         626 (52)                166 (71)                   36 (77)                  
  No                                       656 (44)         576 (47)                69 (29)                    11 (23)                  
  Not available                            6 (0.40)         6 (0.50)                0                          0                        
  No. of retrieved LNs, median (IQR)       28 (19, 41)      26 (18, 39)             38 (26, 52)                30 (21, 43)             \<.0001
  T category                                                                                                                           \<.0001
  T1                                       355 (24)         347 (28)                6 (2)                      2 (4)                    
  T2                                       375 (25)         338 (28)                30 (13)                    7 (15)                   
  T3                                       690 (46)         480 (40)                176 (75)                   34 (72)                  
  T4                                       70 (5)           43 (4)                  23 (10)                    4 (9)                    
  N category                                                                                                                           \<.0001
  N0                                       877 (59)         771 (64)                86 (37)                    20 (43)                  
  N1                                       377 (25)         283 (23)                79 (34)                    15 (32)                  
  N2                                       236 (16)         154 (13)                70 (30)                    12 (25)                  
  TNM stage (UICC 8th)                                                                                                                 \<.0001
  I                                        564 (38)         530 (44)                25 (11)                    9 (19)                   
  II                                       313 (21)         241 (20)                61 (26)                    11 (23)                  
  III                                      613 (41)         437 (36)                149 (63)                   27 (58)                  
  Circumferential resection margin                                                                                                     .1979
  Negative                                 1438 (97)        1171 (97)               222 (94)                   45 (96)                  
  Positive                                 52 (3)           37 (3)                  13 (6)                     2 (4)                    
  Adjuvant chemotherapy                                                                                                                \<.0001
  Yes                                      367 (25)         257 (21)                100 (43)                   10 (21)                  
  No                                       1123 (75)        951 (79)                135 (57)                   37 (79)                  
  Preoperative CEA, median (IQR)           2.6 (1.6, 4.4)   2.3 (1.5, 3.3)          10.7 (7.1, 23.7)           11.4 (7, 42.3)          \<.0001

Data are expressed as n (%) unless otherwise specified.

Abbreviations: CEA, carcinoembryonic antigen; LN, lymph node.
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Fourteen patients received postoperative radiation. Of these, seven had positive CRM, three had lateral LN metastases, and four underwent transanal resection. Twelve patients had normal preoperative CEA levels and two had elevated preoperative but normalized postoperative CEA levels.

3.2. Long‐term outcomes after curative resection {#cam42758-sec-0012}
------------------------------------------------

Figure [2](#cam42758-fig-0002){ref-type="fig"}A,B show RFS and OS curves by group (*P* \< .0001 and *P* \< .0001, respectively). The 5‐year RFS and 5‐year OS rates were 78.0% and 90.7%, respectively, for the normal group (n = 1208), 65.1% and 80.5%, respectively, for the normalized group (n = 235), and 49.6% and 61.1%, respectively, for the elevated group (n = 47).

![Recurrence‐free survival curves (A) and overall survival curves (B) for the normal group (normal preoperative CEA), normalized group (elevated preoperative and normalized postoperative CEA), and elevated group (elevated preoperative and postoperative CEA). C, Hazard function curves for each group, indicating the instantaneous conditional recurrence or death at time *t*](CAM4-9-653-g002){#cam42758-fig-0002}

Bonferroni correction for multiple comparisons revealed a worse RFS in the normalized group compared to the normal group (*P* \< .0001), and no significant difference in RFS between the normalized group and elevated group (*P* = .0721). Moreover, the normalized group had a worse OS than the normal group (*P *= .0001), but a better OS than the elevated group (*P* = .0016).

3.3. Hazard functions for disease recurrence {#cam42758-sec-0013}
--------------------------------------------

Figure [2](#cam42758-fig-0002){ref-type="fig"}C shows hazard function curves by group. These curves represent the instantaneous risk for the event at each time‐point, whereas Kaplan‐Meier survival curves represent the cumulative risk. The elevated group had the highest and earliest peak in hazard function (peak rate: 0.023, peak months: 0), followed by the normalized group (peak rate: 0.011, peak months: 4.6) and the normal group (peak rate: 0.0054, peak months: 8.1). The median time to recurrence from operation was shortest for the elevated group at 8.8 months, followed by the normalized group (15.5 months) and the normal group (18.5 months) (Table 3; *P* = .0223).

3.4. Stage‐specific long‐term outcomes after curative resection {#cam42758-sec-0014}
---------------------------------------------------------------

The 5‐year OS rate was 95.5% (95% CI 93.2‐97.0) for 564 stage I patients, 90.2% (95% CI 86.1‐93.1) for 313 stage II patients, and 79.4% (95% CI 75.9%‐82.6%) for 613 stage III patients (Table [2](#cam42758-tbl-0002){ref-type="table"}).

###### 

Univariable and multivariable analyses of overall survival

                                           No. of patients   5‐year OS   95% CI      *P*         HR           95% CI       *P*
  ---------------------------------------- ----------------- ----------- ----------- ----------- ------------ ------------ -------
  Age, y                                                                                                                   
  \<65                                     906               90.2        88.0‐92.0   \<.0001     Reference                  
  ≥65                                      584               83.6        80.2‐86.6   1.95        1.50‐2.54    \<.0001      
  Operation year                                                                                                           
  2000‐2007                                816               85.4        82.8‐87.7   .0006       1.67         1.21‐2.29    .0017
  2008‐2015                                674               91.0        88.2‐93.1   Reference                             
  Sex                                                                                                                      
  male                                     1001              86.0        83.5‐88.1   .0021       1.57         1.16‐2.13    .0033
  female                                   489               91.3        88.2‐93.6   Reference                             
  Tumor distance from the anal verge, cm                                                                                   
  ≤5                                       670               85.9        82.9‐88.5   .0284       1.23         0.952‐1.59   .1125
  \>5                                      820               89.0        86.5‐91.0   Reference                             
  Tumor differentiation                                                                                                    
  well                                     803               91.7        89.5‐93.5   \<.0001     Reference                  
  moderate                                 615               84.7        81.5‐87.5   1.32        1.00‐1.74    .0479        
  poor                                     71                66.6        53.5‐77.5   1.71        1.06‐2.77    .0276        
  Lymphatic invasion                                                                                                       
  yes                                      457               80.7        76.7‐84.2   \<.0001     1.59         1.20‐2.09    .0010
  no                                       1028              90.8        88.8‐92.5   Reference                             
  Venous invasion                                                                                                          
  yes                                      828               84.0        81.2‐86.5   .0001       1.27         0.954‐1.70   .1012
  no                                       656               92.1        89.7‐94.0   Reference                             
  No. of retrieved LNs                                                                                                     
  ≥12                                      1380              87.6        85.6‐89.3   .815        Reference                  
  \<12                                     110               89.4        81.9‐94.0   1.46        0.904‐2.37   .1215        
  TNM stage (UICC 8th)                                                                                                     
  I                                        564               95.5        93.2‐97.0   \<.0001     Reference                  
  II                                       313               90.2        86.1‐93.1   1.78        1.14‐2.80    .0118        
  III                                      613               79.4        75.9‐82.6   3.11        2.04‐4.74    \<.0001      
  Circumferential resection margin                                                                                         
  Negative                                 1438              88.2        86.3‐90.0   .0015       Reference                  
  Positive                                 52                73.5        58.8‐84.4   1.79        1.03‐3.12    .0400        
  Adjuvant chemotherapy                                                                                                    
  yes                                      367               83.0        78.6‐86.7   .0074       0.786        0.565‐1.09   .1529
  no                                       1123              89.2        87.1‐91.0   Reference                             
  CEA group                                                                                                                
  normal                                   1208              90.7        88.1‐91.7   \<.0001     Reference                  
  normalized                               235               80.5        74.5‐85.3   1.45        1.06‐2.00    .0211        
  elevated                                 47                61.1        45.4‐74.7   2.64        1.62‐4.29    \<.0001      

Abbreviations: OS: overall survival, CI: confidence interval, HR: hazard ratio, LN: lymph node, CEA: carcinoembryonic antigen.

John Wiley & Sons, Ltd

Among stage III patients, stage‐specific RFS and OS rates significantly differed by group (RFS: HR 1.52, 95% CI 1.14‐2.03 for normalized vs normal groups (*P* = .0042) and HR 2.38, 95% CI 1.47‐3.87 for elevated vs normal groups (*P* = .0004); OS: HR 1.50, 95% CI 1.03‐2.18 for normalized vs normal groups (*P* = .0350) and HR 3.23, 95% CI 1.85‐5.63 for elevated vs normal groups (*P *\< .0001)) (Figure S1). On the other hand, among stage I/II patients, both stage‐specific RFS and OS rates showed no significant differences by group (Figure S1).

3.5. Factors affecting prognosis after curative resection {#cam42758-sec-0015}
---------------------------------------------------------

In terms of RFS, univariable analysis revealed that age (≥65 years; *P* = .0012), sex (male; *P* = .0014), tumor distance from the anal verge (≤5 cm; *P* = .0013), tumor differentiation (moderate or poor; *P* \< .0001), lymphatic invasion (present; *P* \< .0001), venous invasion (present; *P* \< .0001), TNM stage (stage II or III; *P* \< .0001), circumferential resection margin (positive; *P* \< .0001), and adjuvant chemotherapy (present; *P* \< .0001) were significantly associated with recurrence. Multivariable analyses using Cox proportional hazards regression models revealed that older age (HR 1.47, 95% CI 1.19‐1.80; *P* = .0003), male (HR 1.45, 95% CI 1.16‐1.83; *P* = .0014), tumor distance from the anal verge ≤ 5 cm (HR 1.36, 95% CI 1.11‐1.66; *P* = .0026), presence of lymphatic invasion (HR 1.69, 95% CI 1.36‐2.09; *P* \< .0001), presence of venous invasion (HR 1.34, 95% CI 1.07‐1.69; *P* = .0127), retrieved LNs \< 12 (HR 1.66, 95% CI 1.13‐2.45; *P* = .0096), advanced TNM stage (stage II vs stage I: HR 2.11, 95% CI 1.50‐2.99; *P* \< .0001, and stage III vs stage I: HR 3.91, 95% CI 2.81‐5.45; *P* \< .0001), and positive circumferential resection margin (HR 2.01, 95% CI 1.34‐3.00; *P* = .0007) were independent predictors of recurrence (Supplementary Table). After adjusting for these clinical factors, 5‐year RFS was worse in the normalized group (HR 1.34, 95% CI 1.04‐1.71; *P* = .0216) compared to the normal group, but did not significantly differ compared to the elevated group (HR 0.76, 95% CI 0.48‐1.22: *P* = .2521) (Supplementary Table).

In terms of overall survival, univariable analysis revealed that age (≥65 years; *P* \< .0001), operation year (2000‐2007; *P* = .0006), sex (male; *P* = .0021), tumor distance from the anal verge ( ≤5; *P* = .0284), tumor differentiation (moderate or poor; *P* \< .0001), lymphatic invasion (present; *P* \< .0001), venous invasion (present; *P* = .0001), TNM stage (stage II or III; *P* \< .0001), and adjuvant chemotherapy (present; *P* = .0074) were significantly associated with worse OS. Multivariable analyses using Cox proportional hazards regression models revealed that older age (HR 1.95, 95% CI 1.50‐2.54; *P* \< .0001), early phase of operation year (2000‐2007 vs 2008‐2015: HR 1.67, 95% CI 1.21‐2.29; *P* = .0017), male (HR 1.57, 95% CI 1.16‐2.13; *P* = .0033), moderate or poor differentiation (moderate vs well: HR 1.32, 95% CI 1.00‐1.74; *P* = .0479, and poor vs well: HR 1.71, 95% CI 1.06‐2.77; *P* = .0276), presence of lymphatic invasion (HR 1.59, 95% CI 1.20‐2.09; *P* = .0010), advanced tumor stage (stage II vs stage I: HR 1.78, 95% CI 1.14‐2.80; *P* = .0118, and stage III vs stage I: HR 3.11, 95% CI 2.04‐4.74; *P* \< .0001), and positive circumferential resection margin (HR 1.79, 95% CI 1.03‐3.12; *P* = .0400) were all independent predictors of worse OS (Table [2](#cam42758-tbl-0002){ref-type="table"}). After adjusting for these clinical factors, the normalized group had worse OS (HR 1.45, 95% CI 1.06‐2.00; *P* = .0211) compared to the normal group, but better OS compared to the elevated group (HR 0.55, 95% CI 0.32‐0.95: *P* = .0305) (Table [2](#cam42758-tbl-0002){ref-type="table"}).

3.6. Recurrence patterns by group {#cam42758-sec-0016}
---------------------------------

During the study period, 315 (21%) patients developed recurrence. The recurrence rates were 6% (35/564) for stage I patients, 19% (58/313) for stage II patients, and 36% (222/613) for stage III patients.

According to CEA levels, recurrence rates were 18% (222/1208) for the normal group, 33% (77/235) for the normalized group, and 34% (16/47) for the elevated group (Table 3), suggesting that patients with elevated preoperative CEA (either with normalized or elevated postoperative CEA) are more prone to recurrence (*P* \< .0001).

Overall local recurrence rate was 5.4% (80/1490). According to CEA levels, 5% (58/1208) in the normal group, 7% (17/235) in the normalized group, and 11% (5/47) in the elevated group developed local recurrence (*P* = .0844).

3.7. Propensity score matching {#cam42758-sec-0017}
------------------------------

Propensity score matching analysis was conducted to balance the distribution of covariates between the normal preoperative CEA group and elevated preoperative CEA group (which includes the normalized and elevated subgroups). After propensity score matching, 280 matched pairs of patients were selected and patient distributions were balanced between the two groups. In the cohort of matched patients (n = 560), the elevated preoperative CEA group had worse OS than the normal preoperative CEA group (*P* = .0024). Specifically, the 5‐year OS for normal and elevated preoperative CEA groups was 86.7% and 77.2%, respectively.

4. DISCUSSION {#cam42758-sec-0018}
=============

We demonstrated that in stage I‐III rectal cancer patients who underwent no preoperative therapy, those with preoperatively elevated and postoperatively normalized CEA following resection of rectal cancer had worse prognoses, both in terms of RFS and OS, compared to those with normal preoperative CEA. These findings are quite different from a previous report of a large‐scale study on colon cancer,[9](#cam42758-bib-0009){ref-type="ref"} which concluded that preoperatively elevated and postoperatively normalized CEA levels is not an indicator of poor prognosis. In contrast, we found that "preoperatively elevated and postoperatively normalized CEA levels" may be a specific indicator of poor prognosis in rectal cancer patients. Thus, the prognostic significance of CEA levels following curative resection of rectal cancer differs from that of colon cancer. On the other hand, our finding that the prognoses of patients with preoperatively elevated and postoperatively normalized CEA were better than those of patients with continuously elevated perioperative CEA is consistent with a previous report.[7](#cam42758-bib-0007){ref-type="ref"} Moreover, those with elevated postoperative CEA had the highest and earliest peak in hazard function, with a significantly shorter median time to recurrence, followed by those with normalized postoperative CEA, and those with normal preoperative CEA, in this order. Meanwhile, recurrence sites showed no significant differences among the three groups. Taken together, our results suggest that patients with elevated preoperative CEA are at high risk of developing early recurrence, both distant and local, after resection of rectal cancer, regardless of whether levels normalize postoperatively or not.

Controversies exist regarding the survival benefits of intensive follow‐up after curative resection of colorectal cancer.[20](#cam42758-bib-0020){ref-type="ref"}, [21](#cam42758-bib-0021){ref-type="ref"}, [22](#cam42758-bib-0022){ref-type="ref"}, [23](#cam42758-bib-0023){ref-type="ref"} In rectal cancer alone, several studies have shown that intensive monitoring is beneficial in terms of detecting treatable residual disease such as local recurrence.[22](#cam42758-bib-0022){ref-type="ref"}, [24](#cam42758-bib-0024){ref-type="ref"}, [25](#cam42758-bib-0025){ref-type="ref"} The results of the present study suggest that patients with rectal cancer showing elevated preoperative CEA may require different surveillance from patients with normal preoperative CEA. Intensive follow‐up might allow for detection of treatable residual disease, thereby improving patient outcomes.

In the present study, stage‐specific RFS and OS rates in patients with stage III rectal cancer, but not stage I or II rectal cancer, differed significantly by group, similar to the previous report.[9](#cam42758-bib-0009){ref-type="ref"} One possible reason for this is the inclusion of patients with falsely elevated CEA in stage I/II, due to the reference range of CEA ≤ 5 ng/ml used in the present study. Indeed, among patients with preoperatively elevated CEA (either with postoperatively normalized or elevated CEA; n =282), median levels of preoperative CEA were 7.4 ng/ml and 9.7 ng/ml in stage I (n = 39) and II (n = 72) patients, respectively, compared to 12.2 ng/ml in stage III (n = 173) patients (*P* = .0037) (data not shown). Thus, stage I/II patients had lower levels of preoperative CEA compared to stage III patients. We analyzed the outcomes using a cutoff CEA level of 10 ng/ml, but results were similar (Figure S2).

The concept of evaluating both preoperative and postoperative CEA levels, which we adopted in this study, might be beneficial in other situations. Recently, several studies have shown that CEA after preoperative chemoradiotherapy is associated with histologic response and prognosis in patients with rectal cancer.[26](#cam42758-bib-0026){ref-type="ref"}, [27](#cam42758-bib-0027){ref-type="ref"}, [28](#cam42758-bib-0028){ref-type="ref"} Those studies suggested that, when combined, pre‐ and post‐chemoradiotherapy CEA could be useful as prognostic factors for disease‐free survival in patients with rectal cancer who undergo treatment with neoadjuvant chemoradiotherapy and curative resection.[26](#cam42758-bib-0026){ref-type="ref"}, [27](#cam42758-bib-0027){ref-type="ref"}, [28](#cam42758-bib-0028){ref-type="ref"} Elevated CEA before preoperative therapy, as well as normalized CEA after preoperative therapy, may also have a specific prognostic impact.

We also analyzed the prognostic significance of serum CA19‐9 levels. Among the 1490 patients of this study cohort, 1472 had information available on preoperative and early postoperative CA19‐9 levels. Similar to the results for CEA, the normalized group had worse OS (n = 103; 5‐year OS 72.7%) compared to the normal group (n = 1350; 5‐year OS 90.7%) and better OS compared to the elevated group (n = 75; 5‐year OS 59.9%) (*P* \< .0001) (data not shown), suggesting that normalized CA19‐9 after surgery may also be a specific prognostic indicator.

Our study has some limitations. First, although our large‐scale study cohort was comprised of prospectively collected series of consecutive patients, the study was retrospective in nature and thus may have had selection bias. Second, this study may not directly reflect clinical practice in many Western countries, where neoadjuvant therapy is the current treatment standard. As described above, several studies in Western countries have investigated CEA changes before and after neoadjuvant therapy.[26](#cam42758-bib-0026){ref-type="ref"}, [27](#cam42758-bib-0027){ref-type="ref"}, [28](#cam42758-bib-0028){ref-type="ref"} However, without the knowledge of perioperative CEA changes in rectal cancer in patients who have not undergone preoperative therapy, the results of these studies cannot be fully understood. In this regard, the present study offers important insights for research studies in Japan as well as Western countries, since we examined baseline changes in perioperative CEA in rectal cancer patients without the influence of preoperative therapy. Third, confounders of CEA, such as smoking, liver disease, and diabetes, were not included in our data for analysis, although they might have resulted in false‐positive CEA elevation. Fourth, due to the observational retrospective design, the timing for early postoperative CEA measurement was not consistent across patients. The half‐life of CEA is 3‐5 days, and serum CEA levels decrease to normal levels from 2 weeks to 1 month. Previous studies also showed considerable variation in the timing of early postoperative CEA measurements (7 days to 1 year after surgery).[6](#cam42758-bib-0006){ref-type="ref"}, [7](#cam42758-bib-0007){ref-type="ref"}, [29](#cam42758-bib-0029){ref-type="ref"}, [30](#cam42758-bib-0030){ref-type="ref"}, [31](#cam42758-bib-0031){ref-type="ref"} In this study, we focused on "early" postoperative CEA and used measurements obtained within 3 months. This period, however, might not have been long enough for recovery from postoperative complications to occur prior to initiation of adjuvant chemotherapy. Fifth, postoperative CEA measurements were not available in 126 patients, who were subsequently excluded from the analysis, and for this reason, generalizing our findings might not be feasible. Nonetheless, our findings regarding perioperative changes in CEA in rectal cancer patients of the largest cohort to date warrant further consideration.

5. CONCLUSION {#cam42758-sec-0019}
=============

Patients with elevated preoperative and normalized postoperative CEA following resection of rectal cancer had worse prognoses compared to those with normal preoperative CEA. Unlike previous reports on colon cancer, perioperative changes in CEA might also have a certain prognostic impact in addition to those of preoperative and postoperative CEA. Moreover, patients with elevated preoperative CEA might require intensive follow‐up, especially in earlier periods, regardless of whether levels normalize postoperatively or not, in order to ensure early detection of recurrence after resection.
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